-+ 0.00%
-+ 0.00%
-+ 0.00%

Regeneron Reports Dupixent Meets All Endpoints in Phase 3 Trial for Allergic Fungal Rhinosinusitis

Reuters·11/07/2025 13:00:39

Please log in to view news